Trending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials
1250 GMT - Merck is among the most mentioned companies across news items over the past 12 hours, according to Factiva data, after the German pharmaceutical-and-chemical group said its multiple sclerosis drug didn't meet expectations in a late-stage trial. The drug didn't show strong enough efficacy in reducing annualized relapse rates and therefore missed the company's aim to match the results of Aubagio, a drug for the disease owned by the French drug giant Sanofi. The news is negative from a strategic point of view, as it reduces the pipeline value, Equita analyst Gianmarco Bonacina says in a research note. However, the analyst also points out that expectations for sales of this drug had been significantly reduced and were almost slashed to zero in April, after Merck flagged liver problems shown by two patients in the sample under examination. Sentiment towards the bruton tyrosine kinase inhibitors won't be helped by Merck's failure of evobrutinib to demonstrate superiority over Aubagio, given the class is already clouded by liver toxicity concerns, Citi analysts write in a note to clients. Now the main drug in the pipeline is xevinapant to treat cancer in the head and neck region, with readout of the Phase 3 trial in the next six months, Equita says. Dow Jones & Co. owns Factiva. (andrea.figueras@wsj.com)
(END) Dow Jones Newswires
December 06, 2023 08:05 ET (13:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters